BioNexus Gene Lab

BioNexus Gene Lab leverages a pioneering blood-based genomic screening (BGS) platform, founded on research by the late Professor Emeritus Dato Dr. Liew Choong-Chin, to detect disease predisposition before symptom onset. The company operates as a US-incorporated public entity (BGLC) with a wholly-owned Malaysian subsidiary, MRNA SCIENTIFIC SDN BHD, serving as its global testing center. Its core offering is a less-invasive blood test that uses FDA-approved reagents and proprietary software to generate predictive risk scores, aiming to shift healthcare towards early intervention and prevention.

A blood-based genomic screening (BGS) platform that analyzes dynamic RNA expression patterns in circulating blood to detect early signatures of disease predisposition, focusing on changes influenced by lifestyle, environment, and early pathology.

Competes against large liquid biopsy firms like Guardant Health and GRAIL that focus on ctDNA. BioNexus differentiates by analyzing dynamic RNA for disease predisposition, offering a broader panel including inflammatory diseases, and building on a legacy of academic research in blood-based genomic signatures.